+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era



Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era



Oncotarget 7(44): 72219-72228



The prognostic value of pretreatment serum beta-2 microglobulin (B2MG) level in advanced Hodgkin lymphoma (HL) patients treated in the modern era has not been well established. We conducted a retrospective study involving 202 advanced classical HL (cHL) patients treated from 1998.5 to 2015.7 to evaluate the impact of serum B2MG level on prognosis. Multivariate analysis showed that serum B2MG level ≥ 2.5 mg/L was an independent predictor for freedom from progression (FFP) (P = 0.001), lymphoma-specific survival (P = 0.030) and overall survival (P = 0.034). The 5-year FFP of patients with serum B2MG level ≥ 2.5 mg/L was 66.8%, compared with 89.7% in patients with B2MG level < 2.5 mg/L (P < 0.001). The traditionally used International Prognostic Score (IPS) remained prognostic for FFP (P = 0.013) but the predictive range narrowed, with 5-year FFP ranging from 90.9% to 62.3%. The 5-year FFP of the 44 patients with both IPS ≥ 3 and serum B2MG ≥ 2.5 mg/L was 50.7%, which was significantly worse than that of the 87 patients with only one of the two factors (81.9%, P < 0.001) or the 71 patients with both B2MG < 2.5 mg/L and IPS < 3 (91.1%, P < 0.001). The difference of FFP between the latter two groups was smaller but also significant (P = 0.038). In summary, our data suggest pretreatment serum B2MG level ≥ 2.5 mg/L was an independent unfavorable prognostic factor in advanced cHL patients treated in the modern era. It improves IPS in predicting the outcomes as the combination of IPS and B2MG indentified a wider prognostic range than IPS alone with a sizable number of patients in different risk groups.

(PDF emailed within 1 workday: $29.90)

Accession: 058637986

Download citation: RISBibTeXText

PMID: 27750215


Related references

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. Medical Oncology 31(9): 185, 2015

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clinical Cancer Research 19(24): 6812-6819, 2014

Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leukemia and Lymphoma 49(11): 2091-2098, 2008

Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma. Oncology 87(1): 40-47, 2014

beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. Journal of B.U.On. 10(1): 59-69, 2007

Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma. Leukemia and Lymphoma 33(5-6): 551-558, 1999

Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. Leukemia and Lymphoma 56(11): 3096-3102, 2016

An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 95(12): 2534-2538, 2002

Serum beta-2 microglobulin as a prognostic factor in patients with Hodgkins lymphoma treated with A BVD or equivalent regimens with or without radiation therapy. Blood 102(11): 273b, November 16, 2003

Serum interleukin-6 and beta-2-microglobulin levels in aggressive lymphoma and in advanced multiple myeloma patients Correlation with disease activity and other prognostic parameters. Blood 86(10 SUPPL 1): 826A, 1995

Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma. Pathology, Research and Practice 209(4): 201-207, 2013

The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica 87(7): 701-8; Discussion 708, 2002

Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer 121(3): 423-431, 2015

The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leukemia and Lymphoma 52(10): 1913-1919, 2012